Composition
- 50 mg sitagliptin /1000 mg metformin hydrochloride
extended release film coated tablets.
- 100 mg sitagliptin /1000 mg metformin hydrochloride
extended release film coated tablets.
|
Indications
Gliptifor is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended release is appropriate.
|
Dosage
The dose of Gliptifor should be individualized on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin. Initial combination therapy or maintenance of combination therapy should be individualized and left to the discretion of the health care provider.
|
How Supplied
Box of 1, 2 or 3 (Al/opaque PVDC) strips, each of 10
extended release film coated tablets and an inner
leaflet.
|
Clinical Pharmacology
Gliptifor tablets combine two antidiabetic medications with complementary mechanisms of action to improve glycemic control in adults with type 2 diabetes:
Sitagliptin:
Sitagliptin is a DPP-4 inhibitor, which exerts its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. By increasing and prolonging active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucosedependent
manner.
Metformin hydrochloride:
Metformin is a biguanide that improves glycemic control in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
|